Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.49 |
| ▸ | HTR6 | P50406 | 9/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR5A | P47898 | 2/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.45 |
| ▸ | HTR3B | O95264 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814732 | 0.85 | KEAP1 (0.46) | TSHRHSD17B10ALDH1A1 | |
| SCHEMBL7823337 | 0.85 | KEAP1 (0.42) | HTR6HTR1AHTR2AHTR7HTR1D | |
| SCHEMBL1843566 | 0.84 | KEAP1 (0.49) | TSHRHSD17B10ALDH1A1HPGDPIM1 | |
| SCHEMBL3584707 | 0.83 | ALOX15 (0.37) | HTR6HTR1AHTR2AHTR7TSHR | |
| SCHEMBL3579186 | 0.78 | ALDH1A1 (0.39) | HTR6HTR1AHTR2AHTR7HTR1D | |
| SCHEMBL8259337 | 0.78 | ADRB1 (0.49) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL15834279 | 0.77 | ADRB1 (0.75) | ADRB1HTR6HTR1AHTR2AHTR7 | |
| SCHEMBL8147688 | 0.76 | ADRB1 (0.53) | ADRB1HTR6HTR1AHTR2AHTR7 | |
| Piperazine SCHEMBL3193494 | 0.76 | TNKS (0.51) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL138181 | 0.75 | KEAP1 (0.44) | HTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| EP-0868424-B1 | 4-PYRIMIDINYL- OR 4-PYRAZINYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTI-BACTERIAL AGENTS | UPJOHN CO (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6465456-B2 | FOR THERAPY OF BACTERIAL DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-15 | — | — | US | disclosed |
| EP-0883611-B1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 2002-07-31 | — | — | EP | disclosed |
| CN-1082952-C | Pyrrolylpiperazinylphenyl oxazolidinone antimicrobials | UPJOHN CO (US) | 2002-04-17 | — | — | CN | disclosed |
| US-20020040142-A1 | Novel isoxazolinone antibacterial agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2002002555-A1 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| CN-1206410-A | Azolyl piperazinyl phenyl oxazolidinone antimicrobials | UPJOHN CO (US) | 1999-01-27 | — | — | CN | disclosed |
| EP-0883611-A1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-16 | — | — | EP | disclosed |
| US-5736545-A | ADMINISTERING TO TREAT BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997030981-A1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040142-A1 | Novel isoxazolinone antibacterial agents | MRPL21, RPS4X, OXA1L | ADRB1 726/4885HTR6 4292/4885HTR1A 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.